The FDA has pushed back its decision on Belite Bio's tinlarebant by three months, moving the expected action date to May 12 from the original Feb. 12 PDUFA date. According to the company, the agency said the extension would provide additional time to review the new drug application.
Tinlarebant is an oral small-molecule candidate for Stargardt disease type 1, or STGD1, a rare genetic eye condition. If approved, it would become the first drug for STGD1 in the U.S., giving the review added importance beyond a routine timing change.
The regulatory and clinical picture
Belite's application rests on a Phase 3 result reported in December 2025. In that study, tinlarebant achieved a 35.7% reduction in lesion growth rate versus placebo, meeting the trial's primary endpoint.
The drug works by reducing vitamin A-related toxins that cause retinal disease in STGD1 patients. Although the target disease is in the eye, the mechanism begins in the liver, where vitamin A-based retinol is created. Tinlarebant targets the transport protein that carries retinol to the eye.
Belite already holds breakthrough therapy, fast track and rare pediatric disease designations from the FDA for STGD1. Those labels can help define regulatory expectations, but they did not prevent the agency from taking extra review time here.
Why the delay matters beyond STGD1
A regulatory win would also support Belite's effort to position tinlarebant in larger retinal diseases. The company is already running a Phase 3 trial in geographic atrophy, where an oral drug would enter a U.S. market with two approved intravitreal injections: Astellas' Izervay and Apellis Pharmaceuticals' Syfovre.
Fierce Biotech also noted that a gene therapy from Ocugen is in mid- to late-stage development for STGD1, with data expected in the first half of 2027. That means Belite still has a chance to define the first approved treatment category in the disease, but the three-month delay postpones a key validation point for both the STGD1 program and the company's broader thesis that an oral retinol-pathway drug can compete in retinal disorders where injections are already established.
Belite's preclinical pipeline also includes LBS-009, an anti-RBP4 oral therapy for non-alcoholic fatty liver disease and type 2 diabetes, but the near-term signal for investors remains the same: the FDA has not rejected tinlarebant, yet it has asked for more time, extending uncertainty around a potentially first-in-class rare eye disease launch.




